JP2009529553A5 - - Google Patents

Download PDF

Info

Publication number
JP2009529553A5
JP2009529553A5 JP2008558710A JP2008558710A JP2009529553A5 JP 2009529553 A5 JP2009529553 A5 JP 2009529553A5 JP 2008558710 A JP2008558710 A JP 2008558710A JP 2008558710 A JP2008558710 A JP 2008558710A JP 2009529553 A5 JP2009529553 A5 JP 2009529553A5
Authority
JP
Japan
Prior art keywords
phe
cys
glu
gly
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008558710A
Other languages
English (en)
Japanese (ja)
Other versions
JP5337493B2 (ja
JP2009529553A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2007/002216 external-priority patent/WO2007104541A2/en
Publication of JP2009529553A publication Critical patent/JP2009529553A/ja
Publication of JP2009529553A5 publication Critical patent/JP2009529553A5/ja
Application granted granted Critical
Publication of JP5337493B2 publication Critical patent/JP5337493B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008558710A 2006-03-16 2007-03-13 セリンプロテアーゼを阻害するペプチドを用いて眼科障害を治療する組成物及び方法 Active JP5337493B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP06360008 2006-03-16
EP06360008.4 2006-03-16
EP06291516.0 2006-09-26
EP06291516 2006-09-26
PCT/EP2007/002216 WO2007104541A2 (en) 2006-03-16 2007-03-13 Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012171140A Division JP2012211194A (ja) 2006-03-16 2012-08-01 セリンプロテアーゼを阻害するペプチドを用いて眼科障害を治療する組成物及び方法

Publications (3)

Publication Number Publication Date
JP2009529553A JP2009529553A (ja) 2009-08-20
JP2009529553A5 true JP2009529553A5 (https=) 2011-03-10
JP5337493B2 JP5337493B2 (ja) 2013-11-06

Family

ID=38292592

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008558710A Active JP5337493B2 (ja) 2006-03-16 2007-03-13 セリンプロテアーゼを阻害するペプチドを用いて眼科障害を治療する組成物及び方法
JP2012171140A Withdrawn JP2012211194A (ja) 2006-03-16 2012-08-01 セリンプロテアーゼを阻害するペプチドを用いて眼科障害を治療する組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012171140A Withdrawn JP2012211194A (ja) 2006-03-16 2012-08-01 セリンプロテアーゼを阻害するペプチドを用いて眼科障害を治療する組成物及び方法

Country Status (12)

Country Link
US (3) US20070270344A1 (https=)
JP (2) JP5337493B2 (https=)
AU (1) AU2007224643B2 (https=)
CA (1) CA2646285C (https=)
DK (1) DK1854477T3 (https=)
ES (2) ES2682646T3 (https=)
HU (2) HUE031701T2 (https=)
LT (2) LT2374472T (https=)
PL (1) PL1854477T3 (https=)
PT (2) PT1854477T (https=)
SI (1) SI2374472T1 (https=)
WO (1) WO2007104541A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
ES2348230T3 (es) 2002-06-07 2010-12-01 Dyax Corp. Prevención y reducción de la isquemia.
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
US20050089515A1 (en) * 2003-08-29 2005-04-28 Dyax Corp. Poly-pegylated protease inhibitors
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
EP1858542A4 (en) * 2005-02-24 2009-08-19 Joslin Diabetes Center Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VASPEREPERMABILITY
ES2524015T3 (es) 2005-12-30 2014-12-03 Dyax Corporation Proteínas de enlazamiento a la metaloproteinasa
WO2007104541A2 (en) * 2006-03-16 2007-09-20 Dyax Corp. Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders
US20100119512A1 (en) * 2007-01-25 2010-05-13 Joslin Diabetes Center Methods of diagnosing, treating, and preventing increased vascular permeability
WO2009079585A2 (en) 2007-12-17 2009-06-25 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins
JP2013533206A (ja) * 2008-10-22 2013-08-22 ダイアクス コーポレーション 炎症性障害のための、プロテアーゼ結合タンパク質を含む併用療法
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
SMT201800552T1 (it) 2010-01-06 2018-11-09 Dyax Corp Proteine che legano la callicreina plasmatica
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
WO2013059439A2 (en) 2011-10-21 2013-04-25 Dyax Corp. Combination therapy comprising an mmp-14 binding protein
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
AU2014240045A1 (en) 2013-03-15 2015-09-10 Dyax Corp. Anti-plasma kallikrein antibodies
ES2715379T3 (es) 2013-10-28 2019-06-04 Bicyclerd Ltd Novedosos polipéptidos
EA038532B1 (ru) 2014-01-21 2021-09-10 Такеда Фармасьютикал Компани Лимитед Способ лечения наследственного ангионевротического отека (hae)
US10428158B2 (en) * 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
EP3376939B1 (en) * 2015-11-18 2022-05-11 University Of Louisville Research Foundation, Inc. Automated methods for the objective quantification of retinal characteristics by retinal region and diagnosis of retinal pathology
RU2622031C1 (ru) * 2015-12-07 2017-06-08 Государственное бюджетное образовательное учреждение высшего профессионального образования "Дагестанская государственная медицинская академия" Министерства здравоохранения РФ Способ комбинированного лечения макулярного отека сетчатки
EP3387018A1 (en) 2015-12-11 2018-10-17 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
GB201522441D0 (en) * 2015-12-18 2016-02-03 Midatech Pharma Wales Ltd Sustained release cyclosporine-loaded microparticles
EP3953395B1 (en) * 2019-04-08 2026-05-06 Biocryst Pharmaceuticals, Inc. Plasma kallikrein inhibitors and methods of use thereof in ocular disorders
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
EP4090427A1 (en) 2020-01-13 2022-11-23 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
LT6899B (lt) * 2020-08-27 2022-04-11 Valstybinis mokslinių tyrimų institutas Fizinių ir technologijos mokslų centras Vario paviršiaus cheminio nikeliavimo būdas, nenaudojant aktyvavimo paladžiu
WO2023144030A1 (en) 2022-01-31 2023-08-03 Oxurion NV Plasma kallikrein inhibitor therapy for anti-vegf sensitization
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444156A (en) * 1985-07-12 1995-08-22 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human plasma prekallikrein
US5217951A (en) * 1986-12-24 1993-06-08 John Lezdey Treatment of inflammation
WO1995021601A2 (en) * 1994-01-11 1995-08-17 Protein Engineering Corporation Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof
ATE277081T1 (de) * 1994-01-11 2004-10-15 Dyax Corp Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
US6057287A (en) * 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US6174859B1 (en) * 1999-04-06 2001-01-16 J & D Sciences, Inc. Method of treatment
DE10060653A1 (de) * 2000-12-06 2002-06-20 Epcos Ag Elektrischer Doppelschicht-Kondensator
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
WO2003066824A2 (en) 2002-02-07 2003-08-14 Aventis Behring Gmbh Albumin-fused kunitz domain peptides
ES2348230T3 (es) * 2002-06-07 2010-12-01 Dyax Corp. Prevención y reducción de la isquemia.
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
EP2386310B1 (en) 2002-08-28 2018-11-07 Dyax Corp. Methods for preserving organs and tissues
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
US20050089515A1 (en) 2003-08-29 2005-04-28 Dyax Corp. Poly-pegylated protease inhibitors
AU2004268144A1 (en) 2003-08-29 2005-03-10 Dyax Corp. Modified protease inhibitors
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
EP1858542A4 (en) * 2005-02-24 2009-08-19 Joslin Diabetes Center Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VASPEREPERMABILITY
US7276480B1 (en) * 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
EP2001500A4 (en) 2006-03-10 2010-07-28 Dyax Corp FORMULATIONS FOR ECALLANTIDE
WO2007104541A2 (en) 2006-03-16 2007-09-20 Dyax Corp. Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders
US8467792B2 (en) * 2006-06-27 2013-06-18 Qualcomm Incorporated Method and apparatus for maintaining call continuity in wireless communication
US20090075887A1 (en) * 2007-08-21 2009-03-19 Genzyme Corporation Treatment with Kallikrein Inhibitors
WO2009026539A1 (en) 2007-08-23 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
JP2013533206A (ja) 2008-10-22 2013-08-22 ダイアクス コーポレーション 炎症性障害のための、プロテアーゼ結合タンパク質を含む併用療法

Similar Documents

Publication Publication Date Title
JP2009529553A5 (https=)
JP2005534647A5 (https=)
JP2008514624A5 (https=)
CA2320371A1 (en) Inotropic and diuretic effects of exendin and glp-1
ES2297902T5 (es) Compuestos novedosos agonistas de exendina
MX2009006348A (es) Nuevos compuestos y sus efectos sobre el conductismo de la alimentacion.
ES2514615T3 (es) Proteínas de dominio Kunitz inhibidores de calicreína y ácidos nucleicos que codifican las mismas
ES2682646T3 (es) Composiciones y métodos para el tratamiento de trastornos oftálmicos
JP2008500281A5 (https=)
Jamieson et al. Organ reperfusion and preservation
Hicks et al. Organ preservation
de Rougemont et al. Preconditioning, organ preservation, and postconditioning to prevent ischemia‐reperfusion injury to the liver
White et al. A cardioprotective preservation strategy employing ex vivo heart perfusion facilitates successful transplant of donor hearts after cardiocirculatory death
US10300029B2 (en) Organ protection solutions and method of use
CN107734967B (zh) 在获得的可移植的心脏中调节钙离子稳态
PE20030820A1 (es) Analogos extendidos de peptido 1 de tipo glucagon
JP2013536804A (ja) 灌流組成物
UA102370C2 (ru) Пептид, фармацевтическая композиция и лекарственное средство, которое его содержит, способ лечения и/или предупреждения диабета и сопутствующих ожирению заболеваний, способ снижения аппетита, снижение поглощения пищи и снижение массы тела
JP2020500163A5 (https=)
CN107105640A (zh) 具有控制的钙离子水平的新型组合物和溶液以及用于再灌注的相关方法和用途
JP2023521491A5 (https=)
DK1506225T4 (da) Hidtil ukendte peptidsammensætninger og anvendelse deraf i fremstillingen af aktive farmaceutiske sammensætninger mod hepatitis c-virus
GB2640988A (en) Amylin analogues
WO2020026227A1 (en) Methods and uses of alpha 1-antitrypsin for preservation of explanted organs
Koksal et al. Attenuation of acute lung injury following lower limb ischemia/reperfusion: the pharmacological approach